


<OAI-PMH xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
         xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
    <responseDate>2025-09-09T13:50:37Z</responseDate>
    <request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:12407816" metadataPrefix="pmc">https://pmc.ncbi.nlm.nih.gov/api/oai/v1/mh/</request>
    
    <GetRecord>
        <record>
    <header>
    <identifier>oai:pubmedcentral.nih.gov:12407816</identifier>
    <datestamp>2025-09-04</datestamp>
    
        
        <setSpec>fsoa</setSpec>
        
    
        
        <setSpec>pmc-open</setSpec>
        
    
</header>
    <metadata>
        
        <article xmlns="https://jats.nlm.nih.gov/ns/archiving/1.4/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.4/ https://jats.nlm.nih.gov/archiving/1.4/xsd/JATS-archivearticle1-4.xsd" xml:lang="en" article-type="research-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Future Sci OA</journal-id><journal-id journal-id-type="iso-abbrev">Future Sci OA</journal-id><journal-id journal-id-type="pmc-domain-id">3121</journal-id><journal-id journal-id-type="pmc-domain">fsoa</journal-id><journal-title-group><journal-title>Future Science OA</journal-title></journal-title-group><issn pub-type="epub">2056-5623</issn><publisher><publisher-name>Taylor &amp; Francis</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12407816</article-id><article-id pub-id-type="pmcid-ver">PMC12407816.1</article-id><article-id pub-id-type="pmcaid">12407816</article-id><article-id pub-id-type="pmcaiid">12407816</article-id><article-id pub-id-type="pmid">40878640</article-id><article-id pub-id-type="doi">10.1080/20565623.2025.2552085</article-id><article-id pub-id-type="publisher-id">2552085</article-id><article-version-alternatives><article-version article-version-type="pmc-version">1</article-version><article-version vocab="JAV" vocab-identifier="http://www.niso.org/publications/rp/RP-8-2008.pdf" vocab-term="Version of Record" article-version-type="VoR">Version of Record</article-version></article-version-alternatives><article-categories><subj-group subj-group-type="article-type"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title>Downregulation of serum Foxc2 in dilated cardiomyopathy: association with disease severity and cardiac function</article-title><alt-title alt-title-type="left-running-head">Y. Cai et al.</alt-title><alt-title alt-title-type="right-running-head">Future Science Oa</alt-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Cai</surname><given-names initials="Y">Yufu</given-names></name><xref rid="AF0001" ref-type="aff">a</xref><xref rid="AF0002" ref-type="aff">b</xref><xref rid="AUFN1" ref-type="author-notes">#</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Huang</surname><given-names initials="Q">Qionghui</given-names></name><xref rid="AF0002" ref-type="aff">b</xref><xref rid="AF0003" ref-type="aff">c</xref><xref rid="AUFN1" ref-type="author-notes">#</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Zhi</surname><given-names initials="S">Shaobin</given-names></name><xref rid="AF0002" ref-type="aff">b</xref><xref rid="AF0003" ref-type="aff">c</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Guo</surname><given-names initials="G">Guixian</given-names></name><xref rid="AF0001" ref-type="aff">a</xref><xref rid="AF0002" ref-type="aff">b</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Huang</surname><given-names initials="M">Mingfeng</given-names></name><xref rid="AF0002" ref-type="aff">b</xref><xref rid="AF0003" ref-type="aff">c</xref><xref rid="AN0001" ref-type="corresp"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-1057-4262</contrib-id><name name-style="western"><surname>Tang</surname><given-names initials="X">Xiaoyan</given-names></name><xref rid="AF0002" ref-type="aff">b</xref><xref rid="AF0003" ref-type="aff">c</xref><xref rid="AF0004" ref-type="aff">d</xref><xref rid="AN0002" ref-type="corresp"/></contrib><aff id="AF0001"><label>a</label><institution>The Fourth Department of Cardiovasular Diseases, Meizhou People&#8217;s Hospital</institution>, <city>Meizhou</city>, <state>Guangdong</state>, <country>P. R. China</country></aff><aff id="AF0002"><label>b</label><institution>Institute of Cardiovascular Disease, Affiliated Meizhou Hospital of Shantou University Medical College</institution>, <city>Meizhou</city>, <country>PR China</country></aff><aff id="AF0003"><label>c</label><institution>Guangdong Engineering Technological Research Center of Molecular Diagnosis in Cardiovascular Diseases</institution>, <city>Meizhou</city>, <country>P. R. China</country></aff><aff id="AF0004"><label>d</label><institution>Emergency Department, Meizhou People&#8217;s Hospital</institution>, <city> Meizhou</city>, <country>P. R. China</country></aff></contrib-group><author-notes><fn id="AUFN1"><label>#</label><p>These authors contributed equally to this work.</p></fn><corresp id="AN0001"><bold>CONTACT</bold> Mingfeng Huang <email xlink:href="mailto:huangmingfeng@mzrmyy.com">huangmingfeng@mzrmyy.com</email><institution>Institute of Cardiovascular Disease, Affiliated Meizhou Hospital of Shantou University Medical College</institution>, <city>Meizhou</city><postal-code>514031</postal-code>, <country>PR China</country></corresp><corresp id="AN0002">Xiaoyan Tang <email xlink:href="mailto:gztxy1171@163.com">gztxy1171@163.com</email><institution>Institute of Cardiovascular Disease, Affiliated Meizhou Hospital of Shantou University Medical College</institution>, <addr-line>No.63 Xinfeng Road, Meijiang District</addr-line>, <city>Meizhou</city><postal-code>514031</postal-code>, <country>P. R. China</country>.</corresp></author-notes><pub-date date-type="pub" publication-format="electronic"><day>29</day><month>8</month><year>2025</year></pub-date><pub-date date-type="collection" publication-format="electronic"><year>2025</year></pub-date><volume>11</volume><issue>1</issue><issue-id pub-id-type="pmc-issue-id">476499</issue-id><elocation-id>2552085</elocation-id><pub-history><event event-type="pmc-release"><date><day>29</day><month>08</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>04</day><month>09</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-09-04 16:25:19.050"><day>04</day><month>09</month><year>2025</year></date></event><event event-type="received"><date><day>22</day><month>6</month><year>2025</year></date></event><event event-type="accepted"><date><day>21</day><month>8</month><year>2025</year></date></event><event event-type="tagger"><event-desc>KnowledgeWorks Global Ltd.</event-desc><date><day>28</day><month>8</month><year>2025</year></date></event><event event-type="build-issue-online"><event-desc>published online in a building issue</event-desc><date><day>28</day><month>8</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>&#169; 2025 The Author(s). Published by Informa UK Limited, trading as Taylor &amp; Francis Group</copyright-statement><copyright-year>2025</copyright-year><copyright-holder>The Author(s)</copyright-holder><license><ali:license_ref specific-use="textmining" content-type="ccbynclicense">https://creativecommons.org/licenses/by-nc/4.0/</ali:license_ref><license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc/4.0/">http://creativecommons.org/licenses/by-nc/4.0/</ext-link>), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. The terms on which this article has been published allow the posting of the Accepted Manuscript in a repository by the author(s) or with their consent.</license-p></license></permissions><self-uri content-type="pmc-pdf" xlink:href="IFSO_11_2552085.pdf"/><self-uri content-type="pdf" xlink:href="IFSO_11_2552085.pdf"/><abstract><title>Abstract</title><sec><title>Background</title><p>Dilated cardiomyopathy (DCM) is one of the most frequent non-ischemic causes of heart failure. Foxc2 has been implicated in cardiovascular disease and angiogenesis, but its role in DCM remains undefined. This study aimed to compare serum Foxc2 levels in DCM and non-DCM patients and to assess its clinical relevance.</p></sec><sec><title>Methods</title><p>In this retrospective study, 92 patients (53 DCM, 39 non-DCM) were enrolled. Based on echocardiographic and clinical evaluations, patients were classified into non-DCM group (n&#8201;=&#8201;39) and DCM group (n&#8201;=&#8201;53). Serum Foxc2 concentrations were measured via ELISA, and correlations were analyzed with echocardiographic parameters and biomarkers (BNP, cTnI). ROC analysis assessed Foxc2&#8217;s diagnostic performance, and Kaplan-Meier analysis evaluated 2-year MACE risk.</p></sec><sec><title>Results</title><p>Serum Foxc2 levels were significantly lower in the DCM group (35.33&#8201;&#177;&#8201;27.99&#8201;&#956;g/mL vs. 77.51&#8201;&#177;&#8201;28.94&#8201;&#956;g/mL), and correlated with cardiac function (positive: LVEF, LVFS; negative: LVEDd, BNP, cTnI). ROC analysis demonstrated high diagnostic accuracy for Foxc2 (AUC 0.862). Patients with Foxc2 levels&#8805; 33.945&#8201;&#956;g/mL showed a reduction in 2-year MACE risk (HR 0.187) compared to those with levels below the threshold.</p></sec><sec><title>Conclusion</title><p>Foxc2 may serve as a promising biomarker for DCM diagnosis and prognosis, supporting for further mechanistic investigations.</p></sec></abstract><abstract abstract-type="plain-language-summary"><title>ARTICLE HIGHLIGHTS</title><p>
<list list-type="order"><list-item><p>Serum Foxc2 is identified as a potential diagnostic and prognostic biomarker for dilated cardiomyopathy (DCM), with significantly lower levels observed in DCM patients compared to controls.</p></list-item><list-item><p>Foxc2 levels are positively correlated with cardiac function parameters (LVEF and LVFS) and negatively associated with markers of disease severity (BNP and LVEDd).</p></list-item><list-item><p>Receiver operating characteristic (ROC) analysis demonstrates strong discriminative ability of Foxc2 for DCM, with an AUC of 0.862 (95% CI: 0.787&#8211;0.937) and an optimal cutoff value of 33.945&#8201;&#956;g/mL yielding 75.5% sensitivity and 87.2% specificity.</p></list-item><list-item><p>Patients with Foxc2&#8201;&#8805;&#8201;33.945&#8201;&#956;g/mL exhibit a lower risk of 2-year major adverse cardiac events (HR = 0.187, 95% CI: 0.076&#8211;0.461, <italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.001), with protection sustained throughout 24-month follow-up.</p></list-item></list>
</p></abstract><abstract abstract-type="graphical"><title>Graphical abstract</title><fig position="anchor" id="UF0001" orientation="portrait"><graphic content-type="color" position="float" orientation="portrait" xlink:href="IFSO_A_2552085_UF0001_C.jpg"/></fig></abstract><kwd-group kwd-group-type="author"><title>Keywords</title><kwd>The forkhead box transcription factor C2</kwd><kwd>Dilated cardiomyopathy</kwd><kwd>biomarker</kwd><kwd>diagnostics</kwd><kwd>cardiology</kwd></kwd-group><support-group><funding-group><award-group><funding-source><institution-wrap><institution>the Scientific Research and Cultivation Project of Meizhou People&#8217;s Hospital</institution></institution-wrap></funding-source><award-id>PY-C2021047, PY-C2022008</award-id></award-group><funding-statement>The study was supported by the Scientific Research and Cultivation Project of Meizhou People&#8217;s Hospital (PY-C2021047, PY-C2022008).</funding-statement></funding-group></support-group><counts><fig-count count="5"/><table-count count="5"/><page-count count="11"/><word-count count="4427"/></counts><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec disp-level="1" id="S0001"><label>1.</label><title>Introduction</title><p>Dilated cardiomyopathy (DCM) represents one of the four classical cardiomyopathy phenotypes and is characterized by left ventricular dilation and systolic dysfunction, with or without biventricular involvement, in the absence of coronary artery disease or other secondary causes such as systemic hypertension or valvular heart disease [<xref rid="CIT0001" ref-type="bibr">1</xref>,<xref rid="CIT0002" ref-type="bibr">2</xref>]. DCM arises from diverse etiologies, encompassing both genetic predispositions and acquired factors such as hypertension, valvular disorders, inflammatory/infectious processes, and toxic exposures [<xref rid="CIT0003" ref-type="bibr">3</xref>]. Notably, even non-genetic forms of DCM are associated with a heightened risk of heart failure (HF) progression, as systolic dysfunction often precedes the onset of clinical symptoms. A key clinical feature of DCM is its frequent coexistence with severe valvular disease, highlighting the contributory role of valvular dysfunction in disease pathogenesis [<xref rid="CIT0004" ref-type="bibr">4</xref>].</p><p>The forkhead box transcription factor C2 (Foxc2), a member of the forkhead family of transcription factors, has been implicated in cardiovascular pathology and angiogenesis [<xref rid="CIT0005" ref-type="bibr">5</xref>]. Foxc2 plays a critical role in cardiac development, including the migration of cardiac neural crest cells, septation of the outflow tract, and ventricular expansion [<xref rid="CIT0006" ref-type="bibr">6</xref>]. Endothelial-specific deficiency of Foxc2 has been shown to promote a hypercoagulable state in venous valves following trauma or critical illness, underscoring its importance in valvular function and diseases [<xref rid="CIT0007" ref-type="bibr">7</xref>]. However, the expression profile of Foxc2 in DCM and its potential involvement in DCM pathogenesis remain poorly understood. The present study aims to examine serum Foxc2 levels in patients with DCM and to explore its potential as a predictive biomarker for the disease.</p></sec><sec sec-type="materials" disp-level="1" id="S0002"><label>2.</label><title>Materials and methods</title><sec disp-level="2" id="S0002-S2001"><label>2.1.</label><title>Study design and participants</title><p>A retrospective study was conducted at Meizhou People&#8217;s Hospital, Meizhou, China. All participants were consecutively enrolled from the Department of Cardiology between January 2019 and December 2022 under uniform clinical protocols to ensure consistency in diagnostic and procedural standards. The diagnosis of dilated cardiomyopathy (DCM) was established according to the American Heart Association criteria [<xref rid="CIT0008" ref-type="bibr">8</xref>], requiring the presence of all the following major features: (1) left ventricular ejection fraction (LVEF) &lt;50% accompanied by left ventricular dilation, and (2) left ventricular end-diastolic diameter (LVEDd) exceeding two standard deviations above the predicted mean based on body surface area. Age-matched non-DCM patients were randomly recruited from the same cardiology department. Normal left ventricular function (LVEF &gt;50%) was confirmed by transthoracic echocardiography. The exclusion criteria included: (1) age &lt; 18&#8201;years; (2) congenital heart disease; (3) ischemic heart disease diagnosed by coronary angiography and electrocardiography; (4) primary valvular disease; (5) lack of documented informed consent; (6) incomplete clinical data. All echocardiographic data were independently reviewed and verified by two board-certified cardiologists blinded to clinical status.</p><p>The ethics committee of Meizhou People&#8217;s Hospital approved this study, with a waiver of written informed consent granted due to the retrospective nature of the study.</p></sec><sec disp-level="2" id="S0002-S2002"><label>2.2.</label><title>Sample collection</title><p>Peripheral venous blood samples were obtained by standard venipuncture within 24&#8201;hours of hospital admission. Samples were collected into ethylenediaminetetraacetic acid (EDTA)-containing tubes and immediately centrifuged to isolate serum, which was stored under appropriate conditions for subsequent analysis.</p></sec><sec disp-level="2" id="S0002-S2003"><label>2.3.</label><title>Measurement of serum Foxc2</title><p>Serum concentrations of Foxc2 were quantified using ELISA kits (Human Foxc2 ELISA Kit: Finetest, EH1422) following the manufacturer&#8217;s standardized protocols. All assays were performed by laboratory technicians blinded to clinical information and patient grouping. Samples were anonymized using randomized numerical codes to ensure unbiased measurement.</p></sec><sec disp-level="2" id="S0002-S2004"><label>2.4.</label><title>Patient follow-up</title><p>Follow-up was conducted by reviewing electronic health records (EHRs) from the date of initial evaluation. The primary endpoint was the occurrence of major adverse cardiovascular events (MACE), defined as a composite of all-cause mortality, acute coronary syndrome (ACS), progressive development of epicardial coronary artery disease (CAD), nonfatal stroke, and hospitalization for HF. Endpoint events were adjudicated by cardiologists blinded to Foxc2 levels. ACS, including ST-segment elevation myocardial infarction (STEMI), non&#8211;ST-segment elevation myocardial infarction (NSTEMI), and unstable angina, was diagnosed based on clinical presentation, electrocardiographic findings, serum troponin I levels, and coronary angiography. Confirmation of ACS diagnosis was performed by an independent, blinded cardiologist. The diagnosis of epicardial CAD was established through imaging evidence of coronary artery stenosis exceeding 50% or a reduced fractional flow reserve, as documented by invasive or noninvasive coronary assessments.</p></sec><sec disp-level="2" id="S0002-S2005"><label>2.5.</label><title>Statistical analysis</title><p>Statistical analyses were performed using SPSS software version 24.0 (IBM Corp., Armonk, NY, USA). Continuous variables were expressed as mean&#8201;&#177;&#8201;standard deviation, and categorical variables were presented as percentages. Between-group comparisons were conducted using the Student&#8217;s <italic toggle="yes">t</italic>-test for continuous variables and the chi-square test or Fisher&#8217;s exact test for categorical variables, as appropriate. The optimal cutoff value of Foxc2 for outcome prediction was determined by Youden&#8217;s index on the ROC curve [<xref rid="CIT0009" ref-type="bibr">9</xref>,<xref rid="CIT0010" ref-type="bibr">10</xref>]. Based on this cutoff, Kaplan&#8211;Meier survival analysis was employed to compare the incidence of MACE between subgroups. All statistical tests were two-tailed, and a P value &lt;0.05 was considered statistically significant.</p></sec></sec><sec sec-type="results" disp-level="1" id="S0003"><label>3.</label><title>Results</title><sec disp-level="2" id="S0003-S2001"><label>3.1.</label><title>Clinical baseline characteristics</title><p>A total of 92 patients were enrolled in this study, including 39 non-DCM patients and 53 patients diagnosed with DCM. There was no significant difference in age between the two groups (62.05&#8201;&#177;&#8201;7.72 vs. 61.62&#8201;&#177;&#8201;12.61&#8201;years, <italic toggle="yes">p</italic>&#8201;=&#8201;0.841). Baseline echocardiographic parameters, biochemical indices, and comorbidities are summarized in <xref rid="t0001" ref-type="table">Table 1</xref>. No difference of SBP, DBP, pulse pressure, cTnI, diabetes, aortic insufficiency and atrial fibrillation was observed between DCM patients and non-DCM patients (all <italic toggle="yes">P</italic>&#8201;&gt;&#8201;0.05). Use of concurrent medications, including &#946;-blockers and renin&#8211;angiotensin&#8211;aldosterone system (RAAS) inhibitors, was also comparable between groups. However, the DCM group had a higher proportion of males (77.4% vs. 48.7%, <italic toggle="yes">p</italic>&#8201;=&#8201;0.004), prevalent hypertension (37.7% vs. 12.8%, <italic toggle="yes">p</italic>&#8201;=&#8201;0.008), mitral insufficiency (0% vs. 39.6%, <italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.001), and HF (2.6% vs. 62.3%, <italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.001). As expected, DCM patients exhibited severe cardiac dysfunction, with markedly reduced LVEF (27.89&#8201;&#177;&#8201;8.59% vs. 64.33&#8201;&#177;&#8201;3.31%, <italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.001) and LVFS (13.66&#8201;&#177;&#8201;4.45% vs. 34.74&#8201;&#177;&#8201;3.01%, <italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.001), alongside elevated LVEDd (64.74&#8201;&#177;&#8201;8.78&#8201;mm vs. 44.44&#8201;&#177;&#8201;3.39&#8201;mm, <italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.001). Moreover, compared with non-DCM patients, BNP (2797.92&#8201;&#177;&#8201;3762.64 vs. 45.92&#8201;&#177;&#8201;118.73&#8201;pg/mL, <italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.001), cTnI (0.217&#8201;&#177;&#8201;0.733 vs. 0.005&#8201;&#177;&#8201;0.005&#8201;ng/mL, <italic toggle="yes">p</italic>&#8201;=&#8201;0.040) and BUN (8.46&#8201;&#177;&#8201;4.44 vs. 6.55&#8201;&#177;&#8201;2.74umol/L, <italic toggle="yes">p</italic>&#8201;=&#8201;0.015) were significantly higher in DCM.</p><table-wrap position="float" id="t0001" orientation="portrait"><label>Table 1.</label><caption><p>Baseline clinical characteristics of the study patients.</p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col width="80pt" span="1"/><col width="80pt" span="1"/><col width="80pt" span="1"/><col width="80pt" span="1"/></colgroup><thead><tr><th align="left" colspan="1" rowspan="1">Characteristics</th><th align="center" colspan="1" rowspan="1">Non-DCM (n&#8201;=&#8201;39)</th><th align="center" colspan="1" rowspan="1">DCM (n&#8201;=&#8201;53)</th><th align="center" colspan="1" rowspan="1"><italic toggle="yes">p-</italic>value (t/&#967;&#178;)</th></tr></thead><tbody valign="top"><tr><td align="left" colspan="1" rowspan="1">Age (years)</td><td align="char" char="." colspan="1" rowspan="1">62.05&#8201;&#177;&#8201;7.72</td><td align="char" char="." colspan="1" rowspan="1">61.62&#8201;&#177;&#8201;12.61</td><td align="char" char="." colspan="1" rowspan="1">0.841</td></tr><tr><td align="left" colspan="1" rowspan="1">Male, n (%)</td><td align="char" char="." colspan="1" rowspan="1">19(48.7)</td><td align="char" char="." colspan="1" rowspan="1">41(77.4)</td><td align="char" char="." colspan="1" rowspan="1">
<bold>0.004</bold>
</td></tr><tr><td align="left" colspan="1" rowspan="1">SBP (mm Hg)</td><td align="char" char="." colspan="1" rowspan="1">126.13&#8201;&#177;&#8201;16.65</td><td align="char" char="." colspan="1" rowspan="1">125.74&#8201;&#177;&#8201;25.21</td><td align="char" char="." colspan="1" rowspan="1">0.929</td></tr><tr><td align="left" colspan="1" rowspan="1">DBP (mm Hg)</td><td align="char" char="." colspan="1" rowspan="1">75.95&#8201;&#177;&#8201;13.05</td><td align="char" char="." colspan="1" rowspan="1">79.85&#8201;&#177;&#8201;15.26</td><td align="char" char="." colspan="1" rowspan="1">0.201</td></tr><tr><td align="left" colspan="1" rowspan="1">Pulse pressure (mm Hg)</td><td align="char" char="." colspan="1" rowspan="1">50.18&#8201;&#177;&#8201;11.14</td><td align="char" char="." colspan="1" rowspan="1">45.89&#8201;&#177;&#8201;16.86</td><td align="char" char="." colspan="1" rowspan="1">0.145</td></tr><tr><td align="left" colspan="1" rowspan="1">LVEF (%)</td><td align="char" char="." colspan="1" rowspan="1">64.33&#8201;&#177;&#8201;3.31</td><td align="char" char="." colspan="1" rowspan="1">27.89&#8201;&#177;&#8201;8.59</td><td align="char" char="." colspan="1" rowspan="1">
<bold>&lt;0.001</bold>
</td></tr><tr><td align="left" colspan="1" rowspan="1">LVFS (%)</td><td align="char" char="." colspan="1" rowspan="1">34.74&#8201;&#177;&#8201;3.01</td><td align="char" char="." colspan="1" rowspan="1">13.66&#8201;&#177;&#8201;4.45</td><td align="char" char="." colspan="1" rowspan="1">
<bold>&lt;0.001</bold>
</td></tr><tr><td align="left" colspan="1" rowspan="1">LVEDd (mm)</td><td align="char" char="." colspan="1" rowspan="1">44.44&#8201;&#177;&#8201;3.39</td><td align="char" char="." colspan="1" rowspan="1">64.74&#8201;&#177;&#8201;8.78</td><td align="char" char="." colspan="1" rowspan="1">
<bold>&lt;0.001</bold>
</td></tr><tr><td align="left" colspan="1" rowspan="1">cTnI (ng/ml)</td><td align="char" char="." colspan="1" rowspan="1">0.005&#8201;&#177;&#8201;0.005</td><td align="char" char="." colspan="1" rowspan="1">0.217&#8201;&#177;&#8201;0.733</td><td align="char" char="." colspan="1" rowspan="1">
<bold>0.040</bold>
</td></tr><tr><td align="left" colspan="1" rowspan="1">BNP (pg/ml)</td><td align="char" char="." colspan="1" rowspan="1">45.92&#8201;&#177;&#8201;118.73</td><td align="char" char="." colspan="1" rowspan="1">2797.92&#8201;&#177;&#8201;3762.64</td><td align="char" char="." colspan="1" rowspan="1">
<bold>&lt;0.001</bold>
</td></tr><tr><td align="left" colspan="1" rowspan="1">BUN (umol/L)</td><td align="char" char="." colspan="1" rowspan="1">6.55&#8201;&#177;&#8201;2.74</td><td align="char" char="." colspan="1" rowspan="1">8.46&#8201;&#177;&#8201;4.44</td><td align="char" char="." colspan="1" rowspan="1">
<bold>0.015</bold>
</td></tr><tr><td align="left" colspan="1" rowspan="1">WBC (10^9 /L)</td><td align="char" char="." colspan="1" rowspan="1">6.82&#8201;&#177;&#8201;1.87</td><td align="char" char="." colspan="1" rowspan="1">7.33&#8201;&#177;&#8201;2.51</td><td align="char" char="." colspan="1" rowspan="1">0.078</td></tr><tr><td align="left" colspan="1" rowspan="1">
<bold>Comorbidities</bold>
</td><td align="center" colspan="1" rowspan="1">&#160;</td><td align="center" colspan="1" rowspan="1">&#160;</td><td align="left" colspan="1" rowspan="1">&#160;</td></tr><tr><td align="left" colspan="1" rowspan="1">Hypertension, n (%)</td><td align="char" char="." colspan="1" rowspan="1">5(12.8)</td><td align="char" char="." colspan="1" rowspan="1">20(37.7)</td><td align="char" char="." colspan="1" rowspan="1">
<bold>0.008</bold>
</td></tr><tr><td align="left" colspan="1" rowspan="1">Diabetes, n (%)</td><td align="char" char="." colspan="1" rowspan="1">6(15.4)</td><td align="char" char="." colspan="1" rowspan="1">9(17.0)</td><td align="char" char="." colspan="1" rowspan="1">0.838</td></tr><tr><td align="left" colspan="1" rowspan="1">Aortic insufficiency, n (%)</td><td align="char" char="." colspan="1" rowspan="1">1(2.6)</td><td align="char" char="." colspan="1" rowspan="1">8(15.1)</td><td align="char" char="." colspan="1" rowspan="1">0.100</td></tr><tr><td align="left" colspan="1" rowspan="1">Mitral insufficiency, n (%)</td><td align="char" char="." colspan="1" rowspan="1">0</td><td align="char" char="." colspan="1" rowspan="1">21(39.6)</td><td align="char" char="." colspan="1" rowspan="1">
<bold>&lt;0.001</bold>
</td></tr><tr><td align="left" colspan="1" rowspan="1">Atrial fibrillation, n (%)</td><td align="char" char="." colspan="1" rowspan="1">1(2.6)</td><td align="char" char="." colspan="1" rowspan="1">4(7.5)</td><td align="char" char="." colspan="1" rowspan="1">0.564</td></tr><tr><td align="left" colspan="1" rowspan="1">Heart Failure, n (%)</td><td align="char" char="." colspan="1" rowspan="1">1(2.6)</td><td align="char" char="." colspan="1" rowspan="1">33(62.3)</td><td align="char" char="." colspan="1" rowspan="1">
<bold>&lt;0.001</bold>
</td></tr><tr><td align="left" colspan="1" rowspan="1">
<bold>Therapies</bold>
</td><td align="center" colspan="1" rowspan="1">&#160;</td><td align="center" colspan="1" rowspan="1">&#160;</td><td align="left" colspan="1" rowspan="1">&#160;</td></tr><tr><td align="left" colspan="1" rowspan="1">&#946;-blocks, n (%)</td><td align="char" char="." colspan="1" rowspan="1">34(87.2)</td><td align="char" char="." colspan="1" rowspan="1">46(86.8)</td><td align="char" char="." colspan="1" rowspan="1">0.957</td></tr><tr><td align="left" colspan="1" rowspan="1">RAAS inhibitors,<break/>n (%)</td><td align="char" char="." colspan="1" rowspan="1">19(48.7)</td><td align="char" char="." colspan="1" rowspan="1">17(32.1)</td><td align="char" char="." colspan="1" rowspan="1">0.106</td></tr></tbody></table><table-wrap-foot><fn id="TF1"><p>Data values are means&#8201;&#177;&#8201;standard deviation or numbers (%). Bolding represented <italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.05. DCM, dilated cardiomyopathy; SBP, systolic blood pressure; DBP, diastolic blood pressure; PP, pulse pressure; LVEF, left ventricular ejection fractions; LVFS, left ventricular fractional shortening; LVEDd, left ventricular end-diastolic diameter; cTnI, cardiac troponin I; BNP, brain natriuretic peptide; BUN, Blood Urea Nitrogen; WBC, white blood cell; AI, aortic insufficiency; MI, mitral insufficiency; AF, atrial fibrillation; HF, heart failure; RAAS, renin aniotension aldosterone system.</p></fn></table-wrap-foot></table-wrap></sec><sec disp-level="2" id="S0003-S2002"><label>3.2.</label><title>The level of Foxc2 in DCM and non-DCM patients</title><p>To assess the expression of Foxc2 in DCM, serum Foxc2 concentrations were measured using ELISA. A significant reduction was observed in the DCM group relative to the non-DCM group (35.33&#8201;&#177;&#8201;27.99 vs. 77.51&#8201;&#177;&#8201;28.94&#8201;&#956;g/mL, <italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.001; <xref rid="t0002" ref-type="table">Table 2</xref> &amp; <xref rid="F0002" ref-type="fig">Figure 2a</xref>). We utilized the <ext-link ext-link-type="pmc:entrez-geo" xlink:href="GSE29819">GSE29819</ext-link> dataset [<xref rid="CIT0011" ref-type="bibr">11</xref>] to confirm Foxc2 expression between healthy controls and DCM patients. The results showed that Foxc2 mRNA was significantly higher in healthy control hearts (n&#8201;=&#8201;12) compared to DCM patients (n&#8201;=&#8201;14, <italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.05, <xref rid="F0002" ref-type="fig">Figure 2b</xref>).</p><table-wrap position="float" id="t0002" orientation="portrait"><label>Table 2.</label><caption><p>The serum levels of Foxc2 between DCM and non-DCM groups.</p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col width="80pt" span="1"/><col width="80pt" span="1"/><col width="80pt" span="1"/><col width="80pt" span="1"/></colgroup><thead><tr><th align="left" colspan="1" rowspan="1">Variable</th><th align="center" colspan="1" rowspan="1">Non-DCM (n&#8201;=&#8201;39)</th><th align="center" colspan="1" rowspan="1">DCM (n&#8201;=&#8201;53)</th><th align="center" colspan="1" rowspan="1"><italic toggle="yes">p</italic>-values</th></tr></thead><tbody valign="top"><tr><td align="left" colspan="1" rowspan="1">Foxc2 (ug/mL)</td><td align="char" char="." colspan="1" rowspan="1">77.51&#8201;&#177;&#8201;28.94</td><td align="char" char="." colspan="1" rowspan="1">35.33&#8201;&#177;&#8201;27.99</td><td align="char" char="." colspan="1" rowspan="1">
<bold>&lt;0.001</bold>
</td></tr></tbody></table><table-wrap-foot><fn id="TF2"><p>Bolding represented <italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.05. <italic toggle="yes">DCM</italic> dilated cardiomyopathy, <italic toggle="yes">Foxc2</italic> forkhead box C2.</p></fn></table-wrap-foot></table-wrap></sec><sec disp-level="2" id="S0003-S2003"><label>3.3.</label><title>Correlation of Foxc2 with baseline characteristics</title><p>Correlation analysis revealed distinct patterns of association between serum Foxc2 levels and clinical parameters (<xref rid="t0003" ref-type="table">Table 3</xref>). No significant associations were detected between Foxc2 levels and age, cardiac troponin I (cTnI), or blood pressure parameters (systolic, diastolic, or pulse pressure; all <italic toggle="yes">p</italic>&#8201;&gt;&#8201;0.05). Notably, Foxc2 levels were positively correlated with LVEF (r&#8201;=&#8201;0.560, <italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.001, <xref rid="F0003" ref-type="fig">Figure 3a</xref>) and LVFS (r&#8201;=&#8201;0.569, <italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.001, <xref rid="F0003" ref-type="fig">Figure 3b</xref>), and negatively correlated with LVEDd (r&#8201;=&#8201;&#8722;0.446, <italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.001, <xref rid="F0003" ref-type="fig">Figure 3c</xref>) and BNP (r&#8201;=&#8201;&#8722;0.278, <italic toggle="yes">p</italic>&#8201;=&#8201;0.007, <xref rid="F0003" ref-type="fig">Figure 3d</xref>), suggesting a specific relationship between Foxc2 and cardiac functional parameters.</p><table-wrap position="float" id="t0003" orientation="portrait"><label>Table 3.</label><caption><p>Correlation analysis with Foxc2.</p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col width="80pt" span="1"/><col width="80pt" span="1"/><col width="80pt" span="1"/></colgroup><thead><tr><th align="left" colspan="1" rowspan="1">Variables</th><th align="center" colspan="1" rowspan="1">Correlation coefficient with Foxc2</th><th align="center" colspan="1" rowspan="1"><italic toggle="yes">p</italic>-value</th></tr></thead><tbody valign="top"><tr><td align="left" colspan="1" rowspan="1">Age (years)</td><td align="char" char="." colspan="1" rowspan="1">&#8722;0.077</td><td align="char" char="." colspan="1" rowspan="1">0.464</td></tr><tr><td align="left" colspan="1" rowspan="1">Male, n (%)</td><td align="char" char="." colspan="1" rowspan="1">0.148</td><td align="char" char="." colspan="1" rowspan="1">0.158</td></tr><tr><td align="left" colspan="1" rowspan="1">LVEF (%)</td><td align="char" char="." colspan="1" rowspan="1">0.560</td><td align="char" char="." colspan="1" rowspan="1">
<bold>&lt;0.001</bold>
</td></tr><tr><td align="left" colspan="1" rowspan="1">LVFS (%)</td><td align="char" char="." colspan="1" rowspan="1">0.569</td><td align="char" char="." colspan="1" rowspan="1">
<bold>&lt;0.001</bold>
</td></tr><tr><td align="left" colspan="1" rowspan="1">LVEDd (mm)</td><td align="char" char="." colspan="1" rowspan="1">&#8722;0.446</td><td align="char" char="." colspan="1" rowspan="1">
<bold>&lt;0.001</bold>
</td></tr><tr><td align="left" colspan="1" rowspan="1">cTnI (ng/ml)</td><td align="char" char="." colspan="1" rowspan="1">&#8722;0.196</td><td align="char" char="." colspan="1" rowspan="1">0.061</td></tr><tr><td align="left" colspan="1" rowspan="1">BNP (pg/ml)</td><td align="char" char="." colspan="1" rowspan="1">&#8722;0.278</td><td align="char" char="." colspan="1" rowspan="1">
<bold>0.007</bold>
</td></tr><tr><td align="left" colspan="1" rowspan="1">SBP (mm Hg)</td><td align="char" char="." colspan="1" rowspan="1">&#8722;0.048</td><td align="char" char="." colspan="1" rowspan="1">0.648</td></tr><tr><td align="left" colspan="1" rowspan="1">DBP (mm Hg)</td><td align="char" char="." colspan="1" rowspan="1">&#8722;0.031</td><td align="char" char="." colspan="1" rowspan="1">0.766</td></tr><tr><td align="left" colspan="1" rowspan="1">Pulse pressure (mm Hg)</td><td align="char" char="." colspan="1" rowspan="1">&#8722;0.041</td><td align="char" char="." colspan="1" rowspan="1">0.700</td></tr></tbody></table><table-wrap-foot><fn id="TF3"><p>Correlations between Foxc2 and clinical baseline characteristics were conducted using Pearson&#8217;s or Spearman&#8217;s correlation test. Bolding represented <italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.05. SBP, systolic blood pressure; DBP, diastolic blood pressure; LVEF, left ventricular ejection fractions; LVFS, left ventricular fractional shortening; LVEDd, left ventricular end-diastolic diameter; cTnI, cardiac troponin I; BNP, brain natriuretic peptide; Foxc2, forkhead box C2.</p></fn></table-wrap-foot></table-wrap></sec><sec disp-level="2" id="S0003-S2004"><label>3.4.</label><title>Univariate and multivariate logistic regression for DCM</title><p>As shown in <xref rid="t0004" ref-type="table">Table 4</xref>, univariate analysis identified BNP (OR: 1.011, 95% CI: 1.004&#8211;1.019, <italic toggle="yes">p</italic>&#8201;=&#8201;0.003), hypertension (OR: 4.121, 95% CI: 1.385&#8211;12.267, <italic toggle="yes">p</italic>&#8201;=&#8201;0.011), HF (OR: 62.700, 95% CI: 7.977&#8211;492.830, <italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.001), and Foxc2 (OR: 0.957, 95% CI: 0.941&#8211;0.974, <italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.001) as predictors of DCM. In multivariate analysis, Foxc2 remained an independent protective factor (OR: 0.802, 95% CI: 0.654&#8211;0.984, <italic toggle="yes">p</italic>&#8201;=&#8201;0.034), supporting its potential role in mitigating DCM risk and progression.</p><table-wrap position="float" id="t0004" orientation="portrait"><label>Table 4.</label><caption><p>Univariate and multivariate logistic regression analysis of DCM.</p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col width="80pt" span="1"/><col width="80pt" span="1"/><col width="80pt" span="1"/><col width="80pt" span="1"/><col width="80pt" span="1"/><col width="80pt" span="1"/><col width="80pt" span="1"/></colgroup><thead><tr><th rowspan="2" align="left" colspan="1">Variables</th><th colspan="3" align="center" rowspan="1">Univariate regression<hr/></th><th colspan="3" align="center" rowspan="1">Multivariate regression<hr/></th></tr><tr><th align="center" colspan="1" rowspan="1">Or</th><th align="center" colspan="1" rowspan="1">(95%CI)</th><th align="center" colspan="1" rowspan="1"><italic toggle="yes">p-</italic>value</th><th align="center" colspan="1" rowspan="1">Or</th><th align="center" colspan="1" rowspan="1">(95%CI)</th><th align="center" colspan="1" rowspan="1"><italic toggle="yes">p-</italic>value</th></tr></thead><tbody valign="top"><tr><td align="left" colspan="1" rowspan="1">SBP (mm Hg)</td><td align="char" char="." colspan="1" rowspan="1">0.999</td><td align="char" char="." colspan="1" rowspan="1">0.980&#8211;1.018</td><td align="char" char="." colspan="1" rowspan="1">0.932</td><td align="left" colspan="1" rowspan="1">&#160;</td><td align="left" colspan="1" rowspan="1">&#160;</td><td align="left" colspan="1" rowspan="1">&#160;</td></tr><tr><td align="left" colspan="1" rowspan="1">DBP (mm Hg)</td><td align="char" char="." colspan="1" rowspan="1">1.020</td><td align="char" char="." colspan="1" rowspan="1">0.989&#8211;1.052</td><td align="char" char="." colspan="1" rowspan="1">0.204</td><td align="left" colspan="1" rowspan="1">&#160;</td><td align="left" colspan="1" rowspan="1">&#160;</td><td align="left" colspan="1" rowspan="1">&#160;</td></tr><tr><td align="left" colspan="1" rowspan="1">Pulse pressure (mm Hg)</td><td align="char" char="." colspan="1" rowspan="1">0.980</td><td align="char" char="." colspan="1" rowspan="1">0.952&#8211;1.009</td><td align="char" char="." colspan="1" rowspan="1">0.170</td><td align="left" colspan="1" rowspan="1">&#160;</td><td align="left" colspan="1" rowspan="1">&#160;</td><td align="left" colspan="1" rowspan="1">&#160;</td></tr><tr><td align="left" colspan="1" rowspan="1">LVEF (%)</td><td align="char" char="." colspan="1" rowspan="1">0.599</td><td align="char" char="." colspan="1" rowspan="1">0.320&#8211;1.122</td><td align="char" char="." colspan="1" rowspan="1">0.109</td><td align="left" colspan="1" rowspan="1">&#160;</td><td align="left" colspan="1" rowspan="1">&#160;</td><td align="left" colspan="1" rowspan="1">&#160;</td></tr><tr><td align="left" colspan="1" rowspan="1">BNP (pg/ml)</td><td align="char" char="." colspan="1" rowspan="1">1.011</td><td align="char" char="." colspan="1" rowspan="1">1.004&#8211;1.019</td><td align="char" char="." colspan="1" rowspan="1">
<bold>0.003</bold>
</td><td align="left" colspan="1" rowspan="1">&#160;</td><td align="left" colspan="1" rowspan="1">&#160;</td><td align="char" char="." colspan="1" rowspan="1">0.265</td></tr><tr><td align="left" colspan="1" rowspan="1">BUN</td><td align="char" char="." colspan="1" rowspan="1">1.192</td><td align="char" char="." colspan="1" rowspan="1">1.014&#8211;1.402</td><td align="char" char="." colspan="1" rowspan="1">0.063</td><td align="left" colspan="1" rowspan="1">&#160;</td><td align="left" colspan="1" rowspan="1">&#160;</td><td align="left" colspan="1" rowspan="1">&#160;</td></tr><tr><td align="left" colspan="1" rowspan="1">Hypertension, n (%)</td><td align="char" char="." colspan="1" rowspan="1">4.121</td><td align="char" char="." colspan="1" rowspan="1">1.385&#8211;12.267</td><td align="char" char="." colspan="1" rowspan="1">
<bold>0.011</bold>
</td><td align="left" colspan="1" rowspan="1">&#160;</td><td align="left" colspan="1" rowspan="1">&#160;</td><td align="char" char="." colspan="1" rowspan="1">0.759</td></tr><tr><td align="left" colspan="1" rowspan="1">Diabetes, n (%)</td><td align="char" char="." colspan="1" rowspan="1">1.125</td><td align="char" char="." colspan="1" rowspan="1">0.364&#8211;3.473</td><td align="char" char="." colspan="1" rowspan="1">0.838</td><td align="left" colspan="1" rowspan="1">&#160;</td><td align="left" colspan="1" rowspan="1">&#160;</td><td align="left" colspan="1" rowspan="1">&#160;</td></tr><tr><td align="left" colspan="1" rowspan="1">Aortic insufficiency, n (%)</td><td align="char" char="." colspan="1" rowspan="1">6.756</td><td align="char" char="." colspan="1" rowspan="1">0.808&#8211;56.463</td><td align="char" char="." colspan="1" rowspan="1">0.078</td><td align="left" colspan="1" rowspan="1">&#160;</td><td align="left" colspan="1" rowspan="1">&#160;</td><td align="left" colspan="1" rowspan="1">&#160;</td></tr><tr><td align="left" colspan="1" rowspan="1">Atrial fibrillation, n (%)</td><td align="char" char="." colspan="1" rowspan="1">3.102</td><td align="char" char="." colspan="1" rowspan="1">0.333&#8211;28.903</td><td align="char" char="." colspan="1" rowspan="1">0.320</td><td align="left" colspan="1" rowspan="1">&#160;</td><td align="left" colspan="1" rowspan="1">&#160;</td><td align="left" colspan="1" rowspan="1">&#160;</td></tr><tr><td align="left" colspan="1" rowspan="1">Heart Failure, n (%)</td><td align="char" char="." colspan="1" rowspan="1">62.700</td><td align="char" char="." colspan="1" rowspan="1">7.977&#8211;492.830</td><td align="char" char="." colspan="1" rowspan="1">
<bold>&lt;0.001</bold>
</td><td align="left" colspan="1" rowspan="1">&#160;</td><td align="left" colspan="1" rowspan="1">&#160;</td><td align="char" char="." colspan="1" rowspan="1">0.870</td></tr><tr><td align="left" colspan="1" rowspan="1">&#946;-blocks, n (%)</td><td align="char" char="." colspan="1" rowspan="1">0.966</td><td align="char" char="." colspan="1" rowspan="1">0.282&#8211;3.307</td><td align="char" char="." colspan="1" rowspan="1">0.957</td><td align="left" colspan="1" rowspan="1">&#160;</td><td align="left" colspan="1" rowspan="1">&#160;</td><td align="left" colspan="1" rowspan="1">&#160;</td></tr><tr><td align="left" colspan="1" rowspan="1">RAAS inhibitors, n (%)</td><td align="char" char="." colspan="1" rowspan="1">0.232</td><td align="char" char="." colspan="1" rowspan="1">0.062&#8211;0.875</td><td align="char" char="." colspan="1" rowspan="1">
<bold>0.031</bold>
</td><td align="left" colspan="1" rowspan="1">&#160;</td><td align="left" colspan="1" rowspan="1">&#160;</td><td align="char" char="." colspan="1" rowspan="1">0.763</td></tr><tr><td align="left" colspan="1" rowspan="1">Foxc2</td><td align="char" char="." colspan="1" rowspan="1">0.957</td><td align="char" char="." colspan="1" rowspan="1">0.941&#8211;0.974</td><td align="char" char="." colspan="1" rowspan="1">
<bold>&lt;0.001</bold>
</td><td align="char" char="." colspan="1" rowspan="1">0.802</td><td align="char" char="." colspan="1" rowspan="1">0.654&#8211;0.984</td><td align="char" char="." colspan="1" rowspan="1">
<bold>0.034</bold>
</td></tr></tbody></table><table-wrap-foot><fn id="TF4"><p>Bolding represented <italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.05. OR, odds ratio; CI, Confidence interval; SBP, systolic blood pressure; DBP, diastolic blood pressure; LVEF, left ventricular ejection fractions; BNP, brain natriuretic peptide; BUN, Blood Urea Nitrogen; RAAS, renin aniotension aldosterone system; Foxc2, forkhead box C2.</p></fn></table-wrap-foot></table-wrap></sec><sec disp-level="2" id="S0003-S2005"><label>3.5.</label><title>Diagnosis and prognostic value of Foxc2 for DCM</title><p>The optimal cutoff of Foxc2 for predicting DCM was determined by receiver operating characteristic (ROC) curves, applying Youden&#8217;s index. At the optimal cutoff value of 33.945&#8201;&#956;g/mL, the ROC analysis demonstrated an AUC of 0.862 (95% CI: 0.787&#8211;0.937, <italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.001, <xref rid="F0004" ref-type="fig">Figure 4</xref> &amp; <xref rid="t0005" ref-type="table">Table 5</xref>), yielding a sensitivity of 75.5% and a specificity of 87.2%. Patients were stratified based on this threshold to evaluate long-term outcomes. Individuals with Foxc2 levels &#8805;33.945&#8201;&#956;g/mL demonstrated a significantly lower 2-year incidence of MACE compared to those with lower levels (HR:0.187, 95%CI:0.0756&#8211;0.4609, <italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.001, <xref rid="F0005" ref-type="fig">Figure 5</xref>). These findings indicate that elevated baseline Foxc2 is associated with a favorable prognosis and sustained protection against cardiovascular events over the 24-month follow-up period.</p><table-wrap position="float" id="t0005" orientation="portrait"><label>Table 5.</label><caption><p>ROC predicts independent risk factors for DCM.</p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col width="80pt" span="1"/><col width="80pt" span="1"/><col width="80pt" span="1"/><col width="80pt" span="1"/><col width="80pt" span="1"/><col width="80pt" span="1"/><col width="80pt" span="1"/></colgroup><thead><tr><th align="left" colspan="1" rowspan="1">Variables</th><th align="center" colspan="1" rowspan="1">AUC</th><th align="center" colspan="1" rowspan="1">95% CI</th><th align="center" colspan="1" rowspan="1">Cutoff</th><th align="center" colspan="1" rowspan="1">Sensitivity<break/>(%)</th><th align="center" colspan="1" rowspan="1">Specificity (%)</th><th align="center" colspan="1" rowspan="1"><italic toggle="yes">p</italic>-value</th></tr></thead><tbody valign="top"><tr><td align="left" colspan="1" rowspan="1">Foxc2 (ug/ml)</td><td align="char" char="." colspan="1" rowspan="1">0.862</td><td align="center" char="." colspan="1" rowspan="1">0.787&#8211;0.937</td><td align="char" char="." colspan="1" rowspan="1">33.945</td><td align="char" char="." colspan="1" rowspan="1">75.5</td><td align="char" char="." colspan="1" rowspan="1">87.2</td><td align="char" char="." colspan="1" rowspan="1">
<bold>&lt;0.001</bold>
</td></tr></tbody></table><table-wrap-foot><fn id="TF5"><p>Bolding represented <italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.05.<italic toggle="yes">ROC</italic> receiver operating characteristic; AUC, area under the curve; Foxc2, forkhead box C2; CI, confidence interval.</p></fn></table-wrap-foot></table-wrap></sec></sec><sec sec-type="discussion" disp-level="1" id="S0004"><label>4.</label><title>Discussion</title><p>This study demonstrates the following key findings: (1) Foxc2 deficiency is associated with increased DCM severity, showing negative associations with hypertension, mitral regurgitation (MR), and HF; (2) Foxc2 levels correlate with cardiac function parameters, displaying significant positive correlations with LVEF and LVFS, and inverse correlations with LVEDd and BNP; and (3) Foxc2 serves as an independent diagnostic marker for DCM, with robust discriminative performance (AUC = 0.862). Collectively, these results suggest that Foxc2 may serve as a promising biomarker and potential therapeutic target in DCM.</p><p>Foxc2, previously recognized as a prognostic marker in solid tumors [<xref rid="CIT0012" ref-type="bibr">12</xref>], plays essential roles in cardiovascular development [<xref rid="CIT0013" ref-type="bibr">13</xref>] and is closely linked to cardiovascular diseases [<xref rid="CIT0014" ref-type="bibr">14</xref>]. During embryogenesis, Foxc2 regulates endothelial gene expression and vasculogenesis [<xref rid="CIT0015" ref-type="bibr">15</xref>], participating in multiple stages of angiogenesis [<xref rid="CIT0016" ref-type="bibr">16</xref>,<xref rid="CIT0017" ref-type="bibr">17</xref>]. Experimental studies have demonstrated that Foxc2 overexpression promotes vascular repair by upregulating CXCR4 expression, thereby enhancing the migratory capacity, adhesive properties, and tissue homing of endothelial progenitor cells (EPCs), which are crucial for the repair of injured vascular endothelium and neointimal hyperplasia suppression [<xref rid="CIT0018" ref-type="bibr">18</xref>]. The current findings extend these prior observations to human DCM, demonstrating concordance between reduced Foxc2 expression at both the mRNA level (based on <ext-link ext-link-type="pmc:entrez-geo" xlink:href="GSE29819">GSE29819</ext-link>) and serum protein level (<xref rid="F0001" ref-type="fig">Figure 1</xref>).</p><fig position="float" id="F0001" orientation="portrait"><label>Figure 1.</label><caption><p>Study design and analytical workflow for evaluating Foxc2 as a diagnostic biomarker in dilated cardiomyopathy. This schematic overview illustrates the study design, including participant enrollment (non-DCM, n&#8201;=&#8201;39; DCM, n&#8201;=&#8201;53), blood sample collection, and ELISA-based quantification of serum Foxc2. Statistical analyses included correlation assessment and receiver operating characteristic (ROC) curve analysis. ROC analysis yielded an AUC of 0.862 (95% CI: 0.787&#8211;0.937), supporting the diagnostic value of Foxc2 in DCM.</p></caption><graphic content-type="color" position="float" orientation="portrait" xlink:href="IFSO_A_2552085_F0001_C.jpg"/></fig><fig position="float" id="F0002" orientation="portrait"><label>Figure 2.</label><caption><p>Foxc2 expression in DCM patients versus non-DCM controls. <bold>(a)</bold> Serum Foxc2 protein concentrations (&#956;g/mL) measured by ELISA in non-DCM (n&#8201;=&#8201;39) and DCM (n&#8201;=&#8201;53) cohorts. Foxc2 decreased in DCM patients compared to non-DCM patients (35.33&#8201;&#177;&#8201;27.99 vs. 77.51&#8201;&#177;&#8201;28.94&#8201;&#956;g/mL). Dots represent individual patients, with horizontal lines indicating group means&#8201;&#177;&#8201;SEM (****; <italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.0001). <bold>(b)</bold> Analysis of the <ext-link ext-link-type="pmc:entrez-geo" xlink:href="GSE29819">GSE29819</ext-link> dataset confirmed reduced Foxc2 mRNA expression in DCM heart tissues (n&#8201;=&#8201;14) relative to non-failing control hearts (n&#8201;=&#8201;12). Bar graphs indicate mean&#8201;&#177;&#8201;SEM (*; <italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.05).</p></caption><graphic content-type="color" position="float" orientation="portrait" xlink:href="IFSO_A_2552085_F0002_C.jpg"/></fig><fig position="float" id="F0003" orientation="portrait"><label>Figure 3.</label><caption><p>Correlation analysis between Foxc2 and cardiac function parameters. <bold>(a)</bold> Positive correlation between Foxc2 and left ventricular ejection fraction (LVEF) (r&#8201;=&#8201;0.560, <italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.001). <bold>(b)</bold> Positive correlation between Foxc2 and left ventricular fractional shortening (LVFS) (r&#8201;=&#8201;0.569, <italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.001). <bold>(c)</bold> Negative correlation between Foxc2 and left ventricular end-diastolic diameter (LVEDd) (r=-0.446, <italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.001). <bold>(d)</bold> Negative correlation between Foxc2 and B-type natriuretic peptide (BNP) levels (r=-0.278, <italic toggle="yes">p</italic>&#8201;=&#8201;0.007).</p></caption><graphic content-type="black-white" position="float" orientation="portrait" xlink:href="IFSO_A_2552085_F0003_B.jpg"/></fig><fig position="float" id="F0004" orientation="portrait"><label>Figure 4.</label><caption><p>ROC curve analysis for diagnosis of DCM. ROC curve analysis demonstrated that serum Foxc2 levels effectively distinguished DCM patients from non-DCM controls, with an AUC of 0.862 (95% CI: 0.787&#8211;0.937). The optimal cutoff value of 33.945&#8201;&#956;g/mL was selected by Youden&#8217;s index (<italic toggle="yes">J</italic><sub>max</sub>=0.627), yielding a sensitivity of 75.5% and specificity of 87.2%.</p></caption><graphic content-type="color" position="float" orientation="portrait" xlink:href="IFSO_A_2552085_F0004_C.jpg"/></fig><p>Our study demonstrates significant correlations between reduced serum Foxc2 levels and markers of cardiac dysfunction, including systolic function (LVEF: r&#8201;=&#8201;0.560; LVFS: r&#8201;=&#8201;0.569; both <italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.001) and elevated BNP (r&#8201;&#8722;&#8201;0.278, <italic toggle="yes">p</italic>&#8201;=&#8201;0.007). These findings are consistent with previous studies in ischemia&#8211;reperfusion models, which reported decreased Foxc2 expression in myocardial tissue following injury. In contrast, Foxc2 overexpression was shown to mitigate myocardial ischemia&#8211;reperfusion injury by reducing inflammation and oxidative stress, thereby exerting a cardioprotective effect [<xref rid="CIT0019" ref-type="bibr">19</xref>]. Genetic ablation studies further support the essential role of Foxc2 in cardiac development. Mice lacking Foxc2 exhibit severe structural abnormalities, including persistent truncus arteriosus and ventricular hypoplasia [<xref rid="CIT0020" ref-type="bibr">20</xref>]. While direct evidence linking Foxc2 to myocardial fibrosis remains limited, emerging research indicates that pathogenic Foxc2 variants impair binding to TBX1 enhancers that regulate TGF-&#946; signaling [<xref rid="CIT0021" ref-type="bibr">21</xref>,<xref rid="CIT0022" ref-type="bibr">22</xref>], thereby providing a molecular link between Foxc2 dysfunction and fibrotic remodeling. Additionally, Foxc2 deficiency has been associated with dysregulation of fibrotic mediators, including upregulation of the pro-fibrotic factor Twist1 and downregulation of anti-fibrotic transcription factors Hand1 and Hand2 [<xref rid="CIT0006" ref-type="bibr">6</xref>], suggesting a regulatory role in fibrotic homeostasis and cardiac remodeling.</p><p>Although these findings support the involvement of Foxc2 in cardioprotection, the retrospective design of this study does not exclude the possibility that reduced Foxc2 levels reflect disease progression rather than causation. DCM is characterized by heterogeneous and progressive left ventricular (LV) systolic dysfunction, which may confound the temporal relationship between biomarker changes and pathophysiology. Stratification by the optimal Foxc2 threshold (33.945&#8201;&#956;g/mL) revealed a significant prognostic distinction. Kaplan&#8211;Meier analysis demonstrated that patients with baseline Foxc2 levels &#8805;33.945&#8201;&#956;g/mL experienced markedly better outcomes compared to those with lower expression (<xref rid="F0005" ref-type="fig">Figure 5</xref>). Specifically, the high-Foxc2 group exhibited a significantly reduced risk of 2-year MACE (HR: 0.187, 95% CI: 0.076&#8211;0.461, <italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.001), with the protective effect sustained throughout the 24-month follow-up period.</p><fig position="float" id="F0005" orientation="portrait"><label>Figure 5.</label><caption><p>Kaplan-Meier analysis of MACE-free survival stratified by Foxc2 expression levels. Patients with DCM were categorized into high (Foxc2&#8201;&#8805;&#8201;33.945&#8201;&#956;g/mL) and low (Foxc2&#8201;&lt;&#8201;33.945&#8201;&#956;g/mL) expression groups based on the ROC-derived cutoff. Kaplan&#8211;Meier analysis showed significantly improved MACE-free survival in the high-Foxc2 group (log-rank <italic toggle="yes">p</italic>&#8201;=&#8201;0.011, HR = 3.14, 95% CI: 0.1435&#8211;0.7808).</p></caption><graphic content-type="color" position="float" orientation="portrait" xlink:href="IFSO_A_2552085_F0005_C.jpg"/></fig><p>Although surgical valve repair and prosthetic valve replacement have significantly reduced mortality associated with valvular disease, there remains a pressing need for noninvasive strategies to prevent or slow disease progression [<xref rid="CIT0023" ref-type="bibr">23</xref>]. Early identification and diagnosis of DCM are essential for improving patient outcomes. Current diagnostic tools, including echocardiography, cTnI, and N-terminal pro&#8211;B-type natriuretic peptide (NT-proBNP), are limited by insufficient specificity, particularly in early-stage disease. Foxc2 has been identified as a critical regulator of mitral valve integrity, and its downregulation has been linked to ventricular remodeling and dysfunction [<xref rid="CIT0024" ref-type="bibr">24&#8211;26</xref>]. In the present study, reduced Foxc2 expression was independently associated with DCM (OR: 0.797, <italic toggle="yes">p</italic>&#8201;=&#8201;0.031; <xref rid="t0004" ref-type="table">Table 4</xref>) and demonstrated high diagnostic specificity (84.6%). Given that 30&#8211;40% of symptomatic DCM patients experience adverse outcomes within one year [<xref rid="CIT0027" ref-type="bibr">27</xref>,<xref rid="CIT0028" ref-type="bibr">28</xref>], the combined diagnostic and prognostic performance of Foxc2 may support earlier clinical intervention and more refined risk stratification.</p><p>Several limitations of this study should be acknowledged. First, this was a single-center, retrospective study with a relatively small sample size. Future investigations with larger, multicenter cohorts are required to validate the generalizability of these findings. Second, the present study did not directly explore the mechanistic role of Foxc2 in DCM pathophysiology. Experimental studies are needed to elucidate the molecular pathways through which Foxc2 contributes to myocardial remodeling. Third, while the predictive value of Foxc2 for DCM diagnosis and prognosis was demonstrated, its utility in predicting disease-related complications, such as mitral regurgitation and HF, remains unexplored and warrants prospective evaluation.</p></sec><sec sec-type="conclusions" disp-level="1" id="S0005"><label>5.</label><title>Conclusion</title><p>Serum Foxc2 levels are significantly reduced in patients with DCM and are closely associated with impaired systolic function. These findings underscore the potential of Foxc2 as a noninvasive biomarker for the diagnosis and risk stratification of DCM, offering new insights for early detection and targeted intervention.</p></sec></body><back><sec disp-level="1" id="S0008"><title>Ethical approval and consent to participate</title><p>This study was reviewed and approved by the Ethics Committee of Meizhou People&#8217;s Hospital (Approval no.2022-CY-32). The requirement for informed written consent was waived given the retrospective study design. Patient privacy was ensured, and the data were anonymized or maintained with confidentiality.</p></sec><sec disp-level="1" id="S0006"><title>Authors&#8217; contributions</title><p>XYT contributed to the conception and design. YFC and GXG contributed to the data acquisition. QHH, SBZ and MFH contributed to the analysis and interpretation of data. XYT and MFH contributed to drafting/revising of article. All authors read and approve the final manuscript.</p></sec><sec sec-type="COI-statement" disp-level="1" id="S0007"><title>Disclosure statement</title><p>No potential conflict of interest was reported by the author(s).</p></sec><sec sec-type="data-availability" disp-level="1" id="S0009"><title>Availability of data and material</title><p>The data supporting the findings of this study have been deposited in the Meizhou People&#8217;s Hospital, which is available from the corresponding author upon reasonable request.</p></sec><ref-list><title>References</title><ref id="CIT0001"><label>1</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Elizabeth</surname><given-names>MM</given-names></string-name>, <string-name name-style="western"><surname>Luisa</surname><given-names>M.</given-names></string-name></person-group><article-title>Dilated cardiomyopathy: Genetic determinants and mechanisms</article-title>. <source>Circ Res</source>. <year>2017</year>;<volume>121</volume>(<issue>7</issue>):<fpage>731</fpage>&#8211;<lpage>748</lpage>.<pub-id pub-id-type="pmid">28912180</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1161/CIRCRESAHA.116.309396</pub-id><pub-id pub-id-type="pmcid">PMC5626020</pub-id></mixed-citation></ref><ref id="CIT0002"><label>2</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Raffaella</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Armando</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Luigi</surname><given-names>S</given-names></string-name>, <etal>et al.</etal></person-group><article-title>Cardiomyopathy and sudden cardiac death: Bridging clinical practice with cutting-edge research</article-title>. <source>Biomedicines</source>. <year>2024</year>;<volume>12</volume>(<issue>7</issue>):1602.<pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/biomedicines12071602</pub-id><pub-id pub-id-type="pmcid">PMC11275154</pub-id><pub-id pub-id-type="pmid">39062175</pub-id></mixed-citation></ref><ref id="CIT0003"><label>3</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Stephane</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Neal</surname><given-names>KL</given-names></string-name>, <string-name name-style="western"><surname>Carsten</surname><given-names>T</given-names></string-name>, <etal>et al.</etal></person-group><article-title>Dilated cardiomyopathy: causes, mechanisms, and current and future treatment approaches</article-title>. <source>Lancet</source>. <year>2023</year>;<volume>402</volume>(<issue>10406</issue>):<fpage>998</fpage>&#8211;<lpage>1011</lpage>.<pub-id pub-id-type="pmid">37716772</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S0140-6736(23)01241-2</pub-id></mixed-citation></ref><ref id="CIT0004"><label>4</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Cong</surname><given-names>Q</given-names></string-name>, <string-name name-style="western"><surname>Yansong</surname><given-names>Q</given-names></string-name>, <string-name name-style="western"><surname>Shanshan</surname><given-names>Z.</given-names></string-name></person-group><article-title>Methylations in dilated cardiomyopathy and heart failure</article-title>. <source>Front Cardiovasc Med</source>. <year>2025</year>;<volume>12</volume>:<fpage>1559550</fpage>.<pub-id pub-id-type="pmid">40290189</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fcvm.2025.1559550</pub-id><pub-id pub-id-type="pmcid">PMC12021892</pub-id></mixed-citation></ref><ref id="CIT0005"><label>5</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Tsutomu</surname><given-names>K.</given-names></string-name></person-group><article-title>Foxc2 transcription factor: a newly described regulator of angiogenesis</article-title>. <source>Trends Cardiovasc Med</source>. <year>2009</year>;<volume>18</volume>(<issue>6</issue>):<fpage>224</fpage>&#8211;<lpage>228</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.tcm.2008.11.003</pub-id><pub-id pub-id-type="pmcid">PMC2674371</pub-id><pub-id pub-id-type="pmid">19185813</pub-id></mixed-citation></ref><ref id="CIT0006"><label>6</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Kimberly</surname><given-names>EI</given-names></string-name>, <string-name name-style="western"><surname>Carlo Donato</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Kristin</surname><given-names>RM</given-names></string-name>, <etal>et al.</etal></person-group><article-title>Foxc2 is required for proper cardiac neural crest cell migration, outflow tract septation, and ventricle expansion</article-title>. <source>Dev Dyn</source>. <year>2018</year>;<volume>247</volume>(<issue>12</issue>):<fpage>1286</fpage>&#8211;<lpage>1296</lpage>.<pub-id pub-id-type="pmid">30376688</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/dvdy.24684</pub-id><pub-id pub-id-type="pmcid">PMC6275097</pub-id></mixed-citation></ref><ref id="CIT0007"><label>7</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Mark</surname><given-names>HH</given-names></string-name>, <string-name name-style="western"><surname>Annie</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Margaret</surname><given-names>N</given-names></string-name>, <etal>et al.</etal></person-group><article-title>Defects in vein valve PROX1/FOXC2 antithrombotic pathway in endothelial cells drive the hypercoagulable state induced by trauma and critical illness</article-title>. <source>J Trauma Acute Care Surg</source>. <year>2023</year>;<volume>95</volume>(<issue>2</issue>):<fpage>197</fpage>&#8211;<lpage>204</lpage>.<pub-id pub-id-type="pmid">37072887</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/TA.0000000000003945</pub-id><pub-id pub-id-type="pmcid">PMC10524206</pub-id></mixed-citation></ref><ref id="CIT0008"><label>8</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Biykem</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Monica</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Jennifer</surname><given-names>C</given-names></string-name>, <etal>et al.</etal></person-group><article-title>Current diagnostic and treatment strategies for specific dilated cardiomyopathies: A scientific statement from the American Heart Association</article-title>. <source>Circulation</source>. <year>2016</year>;<volume>134</volume>(<issue>23</issue>):<fpage>e579</fpage>&#8211;<lpage>e646</lpage>.<pub-id pub-id-type="pmid">27832612</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1161/CIR.0000000000000455</pub-id></mixed-citation></ref><ref id="CIT0009"><label>9</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Gaetano</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Valeria</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Rosa</surname><given-names>F</given-names></string-name>, <etal>et al.</etal></person-group><article-title>We are what we eat: Impact of food from short supply chain on metabolic syndrome</article-title>. <source>J Clin Med</source>. <year>2019</year>;<volume>8</volume>(<issue>12</issue>):2061.<pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/jcm8122061</pub-id><pub-id pub-id-type="pmcid">PMC6947359</pub-id><pub-id pub-id-type="pmid">31771147</pub-id></mixed-citation></ref><ref id="CIT0010"><label>10</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Fatemeh</surname><given-names>HM</given-names></string-name>, <string-name name-style="western"><surname>Amir Hossein</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Vahid</surname><given-names>P</given-names></string-name>, <etal>et al.</etal></person-group><article-title>Clinical evaluation of the diagnostic role of MicroRNA-155 in breast cancer</article-title>. <source>Int J Genomics</source>. <year>2020</year>;<volume>2020</volume>:<fpage>9514831</fpage>.<pub-id pub-id-type="pmid">32964011</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1155/2020/9514831</pub-id><pub-id pub-id-type="pmcid">PMC7495225</pub-id></mixed-citation></ref><ref id="CIT0011"><label>11</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Anna</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Patrick</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Peter</surname><given-names>E</given-names></string-name>, <etal>et al.</etal></person-group><article-title>Myocardial transcriptome analysis of human arrhythmogenic right ventricular cardiomyopathy</article-title>. <source>Physiol Genomics</source>. <year>2011</year>;<volume>44</volume>(<issue>1</issue>):<fpage>99</fpage>&#8211;<lpage>109</lpage>.<pub-id pub-id-type="pmid">22085907</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1152/physiolgenomics.00094.2011</pub-id></mixed-citation></ref><ref id="CIT0012"><label>12</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Long</surname><given-names>Z</given-names></string-name>, <string-name name-style="western"><surname>Yong</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Xiaohong</surname><given-names>T</given-names></string-name>, <etal>et al.</etal></person-group><article-title>FOXC2 as a prognostic marker and a potential molecular target in patients with human solid tumors</article-title>. <source>Front Surg</source>. <year>2022</year>;<volume>9</volume>:<fpage>960698</fpage>. doi: <pub-id pub-id-type="doi">10.3389/fsurg.2022.960698</pub-id><pub-id pub-id-type="pmid">36425886</pub-id><pub-id pub-id-type="pmcid">PMC9679010</pub-id></mixed-citation></ref><ref id="CIT0013"><label>13</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>K</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>J</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>T</surname><given-names>JM</given-names></string-name>, <etal>et al.</etal></person-group><article-title>The murine winged helix transcription factors, Foxc1 and Foxc2, are both required for cardiovascular development and somitogenesis</article-title>. <source>Genes Dev</source>. <year>2001</year>;<volume>15</volume>(<issue>18</issue>):2470.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1101/gad.907301</pub-id><pub-id pub-id-type="pmcid">PMC312788</pub-id><pub-id pub-id-type="pmid">11562355</pub-id></mixed-citation></ref><ref id="CIT0014"><label>14</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Tsutomu</surname><given-names>K.</given-names></string-name></person-group><article-title>The cooperative roles of Foxc1 and Foxc2 in cardiovascular development</article-title>. <source>Adv Exp Med Biol</source>. <year>2009</year>;<volume>665</volume>:<fpage>63</fpage>.<pub-id pub-id-type="pmid">20429416</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/978-1-4419-1599-3_5</pub-id></mixed-citation></ref><ref id="CIT0015"><label>15</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Oliver</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Prakash</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Christopher</surname><given-names>S</given-names></string-name>, <etal>et al.</etal></person-group><article-title>Human venous valve disease caused by mutations in FOXC2 and GJC2</article-title>. <source>J Exp Med</source>. <year>2017</year>;<volume>214</volume>(<issue>8</issue>):<fpage>2437</fpage>&#8211;<lpage>2452</lpage>.<pub-id pub-id-type="pmid">28724617</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1084/jem.20160875</pub-id><pub-id pub-id-type="pmcid">PMC5551565</pub-id></mixed-citation></ref><ref id="CIT0016"><label>16</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Hisaki</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Hideto</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Seungwoon</surname><given-names>S</given-names></string-name>, <etal>et al.</etal></person-group><article-title>The Foxc2 transcription factor regulates angiogenesis via induction of integrin beta3 expression</article-title>. <source>J Biol Chem</source>. <year>2008</year>;<volume>283</volume>(<issue>35</issue>):<fpage>23791</fpage>&#8211;<lpage>23800</lpage>.<pub-id pub-id-type="pmid">18579532</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1074/jbc.M800190200</pub-id><pub-id pub-id-type="pmcid">PMC2527100</pub-id></mixed-citation></ref><ref id="CIT0017"><label>17</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Hisaki</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Tsutomu</surname><given-names>K.</given-names></string-name></person-group><article-title>Foxc2 transcription factor as a regulator of angiogenesis via induction of integrin beta3 expression</article-title>. <source>Cell Adh Migr</source>. <year>2009</year>;<volume>3</volume>(<issue>1</issue>):<fpage>24</fpage>&#8211;<lpage>26</lpage>.<pub-id pub-id-type="pmid">19372730</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.4161/cam.3.1.7252</pub-id><pub-id pub-id-type="pmcid">PMC2675144</pub-id></mixed-citation></ref><ref id="CIT0018"><label>18</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Dujuan</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Dan</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Weishuo</surname><given-names>L</given-names></string-name>, <etal>et al.</etal></person-group><article-title>Foxc2 overexpression enhances benefit of endothelial progenitor cells for inhibiting neointimal formation by promoting CXCR4-dependent homing</article-title>. <source>J Vasc Surg</source>. <year>2011</year>;<volume>53</volume>(<issue>6</issue>):<fpage>1668</fpage>&#8211;<lpage>1678</lpage>.<pub-id pub-id-type="pmid">21514778</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jvs.2011.01.044</pub-id></mixed-citation></ref><ref id="CIT0019"><label>19</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Rui</surname><given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Yonggang</surname><given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Shoutao</surname><given-names>J.</given-names></string-name></person-group><article-title>FOXC2 alleviates myocardial ischemia-reperfusion injury in rats through regulating Nrf2/HO-1 signaling pathway</article-title>. <source>Dis Markers</source>. <year>2021</year>;<volume>2021</volume>:<fpage>9628521</fpage>.<pub-id pub-id-type="pmid">34858542</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1155/2021/9628521</pub-id><pub-id pub-id-type="pmcid">PMC8632424</pub-id></mixed-citation></ref><ref id="CIT0020"><label>20</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Joshua</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Risa</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Andrew</surname><given-names>C</given-names></string-name>, <etal>et al.</etal></person-group><article-title>Conditional inactivation of Foxc1 and Foxc2 in neural crest cells leads to cardiac abnormalities</article-title>. <source>Genesis</source>. <year>2020</year>;<volume>58</volume>(<issue>7</issue>):e23364.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/dvg.23364</pub-id><pub-id pub-id-type="pmcid">PMC7363575</pub-id><pub-id pub-id-type="pmid">32259372</pub-id></mixed-citation></ref><ref id="CIT0021"><label>21</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Wei</surname><given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Bojian</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Fen</surname><given-names>L</given-names></string-name>, <etal>et al.</etal></person-group><article-title>Variants in FOXC1 and FOXC2 identified in patients with conotruncal heart defects</article-title>. <source>Genomics</source>. <year>2024</year>;<volume>116</volume>(<issue>3</issue>):<fpage>110840</fpage>. doi: <pub-id pub-id-type="doi">10.1016/j.ygeno.2024.110840</pub-id><pub-id pub-id-type="pmid">38580085</pub-id></mixed-citation></ref><ref id="CIT0022"><label>22</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Jesus</surname><given-names>S-M</given-names></string-name>, <string-name name-style="western"><surname>Antonio</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Mari Carmen</surname><given-names>A-L</given-names></string-name>, <etal>et al.</etal></person-group><article-title>The TBX1 transcription factor in cardiac remodeling after myocardial infarction</article-title>. <source>Rev Esp Cardiol Engl Ed</source>. <year>2016</year>;69(<issue>11</issue>):<fpage>1042</fpage>-<lpage>1050</lpage>.<pub-id pub-id-type="pmid">27422448</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.rec.2016.04.033</pub-id></mixed-citation></ref><ref id="CIT0023"><label>23</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Karthik</surname><given-names>MK</given-names></string-name>, <string-name name-style="western"><surname>Kaitlyn</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Toni</surname><given-names>W</given-names></string-name>, <etal>et al.</etal></person-group><article-title>Biology and biomechanics of the heart valve extracellular matrix</article-title>. <source>J Cardiovasc Dev Dis</source>. <year>2020</year>;<volume>7</volume>(<issue>4</issue>):57.<pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/jcdd7040057</pub-id><pub-id pub-id-type="pmcid">PMC7765611</pub-id><pub-id pub-id-type="pmid">33339213</pub-id></mixed-citation></ref><ref id="CIT0024"><label>24</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>W</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>L</surname><given-names>N-F.</given-names></string-name></person-group><article-title>FOXC2 transcription factor: a novel regulator of lymphangiogenesis</article-title>. <source>Lymphology</source>. <year>2011</year>;<volume>44</volume>(<issue>1</issue>):<fpage>35</fpage>&#8211;<lpage>41</lpage>.<pub-id pub-id-type="pmid">21667821</pub-id></mixed-citation></ref><ref id="CIT0025"><label>25</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Can</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Zhi-Dong</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Shreya</surname><given-names>K</given-names></string-name>, <etal>et al.</etal></person-group><article-title>FOXC1 and FOXC2 ablation causes abnormal valvular endothelial cell junctions and lymphatic vessel formation in myxomatous mitral valve degeneration</article-title>. <source>Arterioscler Thromb Vasc Biol</source>. <year>2024</year>;<volume>44</volume>(<issue>9</issue>):<fpage>1944</fpage>&#8211;<lpage>1959</lpage>. doi: <pub-id pub-id-type="doi">10.1161/ATVBAHA.124.320316</pub-id><pub-id pub-id-type="pmid">38989578</pub-id><pub-id pub-id-type="pmcid">PMC11335087</pub-id></mixed-citation></ref><ref id="CIT0026"><label>26</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Yen-Chun</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Xin</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Anna</surname><given-names>OD</given-names></string-name>, <etal>et al.</etal></person-group><article-title>PROX1 inhibits PDGF-B expression to prevent myxomatous degeneration of heart valves</article-title>. <source>Circ Res</source>. <year>2023</year>;<volume>133</volume>(<issue>6</issue>):<fpage>463</fpage>&#8211;<lpage>480</lpage>.<pub-id pub-id-type="pmid">37555328</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1161/CIRCRESAHA.123.323027</pub-id><pub-id pub-id-type="pmcid">PMC10487359</pub-id></mixed-citation></ref><ref id="CIT0027"><label>27</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Po-Yuan</surname><given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Wei-Chieh</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Chun-Min</surname><given-names>F</given-names></string-name>, <etal>et al.</etal></person-group><article-title>Long-term outcomes and prognosticators of pediatric primary dilated cardiomyopathy in an Asian cohort</article-title>. <source>Front Pediatr</source>. <year>2021</year>;<volume>9</volume>:<fpage>771283</fpage>.<pub-id pub-id-type="pmid">34796157</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fped.2021.771283</pub-id><pub-id pub-id-type="pmcid">PMC8593174</pub-id></mixed-citation></ref><ref id="CIT0028"><label>28</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>William</surname><given-names>YS</given-names></string-name>, <string-name name-style="western"><surname>Margarita</surname><given-names>M-B</given-names></string-name>, <string-name name-style="western"><surname>Alan</surname><given-names>WN</given-names></string-name>, <etal>et al.</etal></person-group><article-title>Long-term outcomes of childhood left ventricular noncompaction cardiomyopathy: results from a national population-based study</article-title>. <source>Circulation</source>. <year>2018</year>;<volume>138</volume>(<issue>4</issue>):<fpage>367</fpage>&#8211;<lpage>376</lpage>.<pub-id pub-id-type="pmid">29514799</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1161/CIRCULATIONAHA.117.032262</pub-id></mixed-citation></ref></ref-list></back></article>
        
    </metadata>
</record>
    </GetRecord>

</OAI-PMH>